NAMPT and neoplasm: Visfatin time- and dose-dependently sustains the epithelial–mesenchymal transition (EMT), a process needed to allow the entrance of tumor cells into the bloodstream and their migration [85], and requires the loss of an epithelial marker (E-cadherin) and the upregulation of a mesenchymal marker (N-cadherin) in U2OS osteosarcoma cells via NF-κB [86].